<div><p><strong><b>Background:</strong> </b>Metabolic dysfunction-associated steatohepatitis (MASH) diagnosis and scoring depend on invasive liver biopsies by measuring metabolic dysfunction-associated steatotic liver disease (MASLD) activity score (NAS) and fibrosis score. However, a quantitative estimation of the combined effect of clinically available laboratory measures and transient elastography parameters (controlled attenuation parameter [CAP] and liver stiffness score [LSM]) as a screening / diagnostic test for advanced MASH has been suggested.

<div><p><strong><b>Background:</strong> </b></p>

<div><p><b>Background:</p> </b><p>Living donor liver transplantation (LDLT) has been increasing in the United States (US). While data exists on longer-term patient and graft outcomes, a contemporary analysis of short-term outcomes is needed to better understand risk factors and opportunities for improvement.</p>

<div><p><b>Background: </b>Comorbidity plays an important role in the mortality of patients both on the waiting list and after liver transplantation (LT). To analyze the impact of comorbidities on LT, a prospective and multicentre study (HEPA_TIC) has been launched.</p>

<div><p><strong> </strong></p>
<p style="font-weight: 400;"><strong><b>Background:</strong> </b></p>

<div><p><b>Background: </b>New treatment concepts focus on enhancing rates of functional cure of chronic hepatitis B (HBV) with the aims of stopping nucleos(t)ide treatment (NA) with no risk of virological relapse or liver disease progression and further decreasing the risk of hepatocellular carcinoma (HCC). Induction of a CD8+ T cell response to HBV is likely a required mechanism to achieve a functional cure.

<div><p><b>Background: </b>While studies have associated social determinants of health (SDOH) with hepatocellular carcinoma (HCC) treatment delay of &gt;3 months, there is limited data on SDOH impacting expedited treatment and subsequent outcomes. This study investigates whether components of SDOH are associated with progression<span>-</span>free survival for HCC within Milan criteria and their effect on time to initiate HCC treatment.</p>

<div><p><b>Background:</p> </b><p>High prevalence of obesity in the U.S. is driving the burden of non-alcoholic steatohepatitis (NASH) and associated adverse clinical outcomes including NASH-related end-stage liver disease and hepatocellular carcinoma (HCC). Our aim was to assess the most recent trends in patients with chronic liver disease (CLD) listed for liver transplantation (LT) in the U.S. using a national registry.</p>

<div><p><b>Background: </b>MAESTRO-MASH (NCT03900429), an ongoing, randomized, double-blind, placebo-controlled Phase 3 serial liver biopsy study, achieved both primary endpoints on liver biopsy (MASH resolution and fibrosis reduction) at Week 52 with both resmetirom doses, including a ≥1-stage reduction in fibrosis without worsening of MASH of 24%, 26% (mITT) at 80 and 100 mg resmetirom compared with placebo (14%).

<div><p><b>Background:</p> </b><p>The 2017 UNOS simultaneous liver-kidney transplant (SLK) policy establishes the minimum eligibility criteria for SLK listing and a mechanism to expedite kidney after liver transplantation (Safety Net). Candidate selection for SLK versus Safety Net requires further refinement.